Perseus Proteomics Inc. (TSE: 4882)
Health Care · Biotechnology · JP
¥147.00
+1.38% today · -56.6% 1Y
Perseus Proteomics Inc. (TSE: 4882) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.04M and employs 35 people.
Over the last twelve months the share price has lost 56.6%, trading between 134.00 and 361.00.
Tweenvest scores Perseus Proteomics Inc. across four factors: quality 33/100, value 45/100, growth 69/100. Its strongest factor is growth.
4882 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.04M
- Revenue (TTM)
- $905.71K
- P/E
- —
- EPS
- -48.06
- Dividend yield
- —
- Beta (5Y)
- 0.32
- 52-week high
- ¥361.00
- 52-week low
- ¥134.00
- Avg volume (3M)
- —
- Shares outstanding
- 18.43M
- Employees
- 35
- Next earnings
- —
About Perseus Proteomics Inc.
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
- ISIN
- JP3836800007
- Founded
- 2001
- Listed since
- Jun 22, 2021
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.94 | +2.92% |
Figures last refreshed Aug 18, 2026.